title: Induction chemotherapy followed by concomitant chemoradiation-induced regression of advanced cervical lymphadenopathy in head and neck cancer as a predictor of outcome.
abstract: OBJECTIVE
  We sought to determine whether induction chemotherapy followed by concomitant chemoradiation (ICCR)-induced advanced neck disease regression could predict outcome, especially the need for complete neck dissection in patients with N2-3 stage IV head and neck cancer (HNC).
  
  
  METHODS
  A retrospective study of 339 patients evaluated for treatment of stage IV HNC during the years 1988 to 1997 revealed 36 individuals with N2-3 cervical lymphadenopathy who were treated with ICCR. Responses to treatment, patterns of failure, and survival rates were analyzed.
  
  
  RESULTS
  Primary and regional tumor regressions were complete in 21 patients (58%), partial in 9 (25%), and absent in 6 (17%); the corresponding local failure rates were 5%, 44%, and 33% (P < 0.02). The regional failure rates were 24%, 89%, and 83%, respectively (P < 0.001); distant failure rates were 10%, 0%, and 0% (P > 0.99). The estimated 2-year survival rates for complete and partial/nonresponders were 57% and 20%, respectively (P < 0.02).
  
  
  CONCLUSIONS
  Patients with advanced regional metastases of HNC who respond completely to ICCR have an excellent chance for survival. However, such ICCR-induced complete regression of regional tumor cannot reliably predict ultimate neck disease control.
authors.affiliation: Department of Radiology, Louisiana State University Health Sciences Center, Shreveport 71130, USA. fampil@lsuhsc.edu
authors.forename: Federico L
authors.initials: FL
authors.lastname: Ampil
authors.forename: Glenn M
authors.initials: GM
authors.lastname: Mills
authors.forename: Gloria
authors.initials: G
authors.lastname: Caldito
authors.forename: Gary V
authors.initials: GV
authors.lastname: Burton
authors.forename: Cherie Ann O
authors.initials: CO
authors.lastname: Nathan
authors.forename: Robert F
authors.initials: RF
authors.lastname: Aarstad
authors.forename: Timothy F
authors.initials: TF
authors.lastname: Lian
authors.forename: Fred J
authors.initials: FJ
authors.lastname: Stucker
authors.forename: John C
authors.initials: JC
authors.lastname: Hardin
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D006258:Head and Neck Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D006801:Humans; D008198:Lymph Nodes / Q000187:drug effects / Q000473:pathology* / Q000528:radiation effects; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D037981:Neck Dissection; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011379:Prognosis; D011829:Radiation Dosage; D018714:Radiotherapy, Adjuvant; D012074:Remission Induction; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome